Steven Boyd’s Armistice Capital: Navigating the Evolving Biotech Investment Landscape
The biotech sector has experienced a rollercoaster ride in recent years, with the COVID-19 pandemic catalyzing unprecedented growth and subsequent challenges. As we look ahead...